STOCK TITAN

[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

United Therapeutics (UTHR): The President and COO reported option exercises and related share sales on 10/27/2025 under a Rule 10b5-1 plan dated June 3, 2025. The reporting person exercised stock options for 14,625 shares at $135.42 and for 6,125 and 1,750 shares at $146.03 through family trusts, then sold 14,625 shares and 7,875 shares at $417.4965.

Following these transactions, indirect holdings shown include 130 shares by one trust. Derivative securities beneficially owned following the transactions include 55,875 options (Trust (2)) and 18,375 options (Trust (3)), with specified vesting and expiration dates.

United Therapeutics (UTHR): Il Presidente e il COO hanno riportato l’esercizio di opzioni e le relative vendite di azioni il 27/10/2025, secondo un piano Rule 10b5-1 datato 3 giugno 2025. La persona che presenta il rapporto ha esercitato opzioni su 14.625 azioni a 135,42 USD e su 6.125 e 1.750 azioni a 146,03 USD tramite trust familiari, poi ha venduto 14.625 azioni e 7.875 azioni a 417,4965 USD.

Dopo queste transazioni, le partecipazioni indirette riportate includono 130 azioni tramite un trust. I titoli derivati di proprietà successiva alle transazioni includono 55.875 opzioni (Trust (2)) e 18.375 opzioni (Trust (3)), con date di vesting ed espirazione specificate.

United Therapeutics (UTHR): El Presidente y el Director de Operaciones reportaron ejercicios de opciones y ventas de acciones relacionadas el 27/10/2025 bajo un plan Rule 10b5-1 con fecha 3 de junio de 2025. La persona reportante ejerció opciones sobre 14.625 acciones a 135,42 USD y sobre 6.125 y 1.750 acciones a 146,03 USD a través de fidecomisos familiares, luego vendió 14.625 acciones y 7.875 acciones a 417,4965 USD.

Después de estas transacciones, las participaciones indirectas mostradas incluyen 130 acciones por un fideicomiso. Los valores derivados de propiedad de modo ventajoso tras las transacciones incluyen 55.875 opciones (Fideicomiso (2)) y 18.375 opciones (Fideicomiso (3)), con fechas de vesting y expiración especificadas.

United Therapeutics (UTHR): 사장 겸 COO는 2025년 10월 27일에 2025년 6월 3일자로 dated된 Rule 10b5-1 계획에 따라 옵션 행사와 관련 주식 매도를 보고했습니다. 보고자는 14,625주를 135.42달러에, 6,125주와 1,750주를 146.03달러에 가족 신탁을 통해 행사한 후, 14,625주와 7,875주를 각각 417.4965달러에 매도했습니다.

이 거래 이후 간접 보유는 하나의 신탁이 보유한 130주를 포함합니다. 거래 이후 실질적으로 소유된 파생증권은 55,875주 옵션(신탁(2))과 18,375주 옵션(신탁(3))으로, 명시된 가용성 및 만료일이 포함됩니다.

United Therapeutics (UTHR): Le président et le directeur des opérations ont signalé des exercices d’options et des ventes d’actions associées le 27/10/2025 dans le cadre d’un plan Rule 10b5-1 daté du 3 juin 2025. La personne faisant le rapport a exercé des options sur 14 625 actions à 135,42 USD et sur 6 125 et 1 750 actions à 146,03 USD via des fiducies familiales, puis a vendu 14 625 actions et 7 875 actions à 417,4965 USD.

Suite à ces transactions, les participations indirectes indiquées comprennent 130 actions par une fiducie. Les titres dérivés détenus à la suite des transactions comprennent 55 875 options (Fiducie (2)) et 18 375 options (Fiducie (3)), avec les dates d’acquisition et d’expiration spécifiées.

United Therapeutics (UTHR): Der Präsident und COO berichteten über Ausübungen von Optionen und damit verbundene Aktienverkäufe am 27.10.2025 im Rahmen eines Rule-10b5-1-Plans vom 03.06.2025. Die meldepflichtige Person hat Optionen über 14.625 Aktien zu 135,42 USD und über 6.125 und 1.750 Aktien zu 146,03 USD über Familienstiftungen ausgeübt, danach wurden 14.625 Aktien und 7.875 Aktien zu 417,4965 USD verkauft.

Nach diesen Transaktionen zeigen indirekte Beteiligungen 130 Aktien durch einen Trust. Die derivativen Wertpapiere, die nach den Transaktionen vorteilhaft besessen werden, umfassen 55.875 Optionen (Trust (2)) und 18.375 Optionen (Trust (3)) mit jeweils festgelegten Vesting- und Ablaufdaten.

United Therapeutics (UTHR): أبلغ الرئيس ونائب رئيس العمليات عن ممارسات خيار ورجوعها وبيع الأسهم المرتبطة في 27/10/2025 بموجب خطة Rule 10b5-1 المؤرخة في 3 يونيو 2025. قامت الشخص المبلِّغ عن упражاء خيارات لــ 14,625 سهماً بسعر 135.42 دولارًا و6,125 و1,750 سهماً بسعر 146.03 دولارًا عبر أمانة عائلية، ثم باع 14,625 سهماً و7,875 سهماً بسعر 417.4965 دولارًا.

بعد هذه المعاملات، تشمل الحيازات غير المباشرة المعروضة 130 سهماً عبر أمانة واحدة. تشمل الأوراق المالية المشتقة المملوكة بموجب المعاملات 55,875 خياراً (Trust (2)) و18,375 خياراً (Trust (3))، مع تواريخ الاستحقاق والاستحقاق المحددة.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

United Therapeutics (UTHR): Il Presidente e il COO hanno riportato l’esercizio di opzioni e le relative vendite di azioni il 27/10/2025, secondo un piano Rule 10b5-1 datato 3 giugno 2025. La persona che presenta il rapporto ha esercitato opzioni su 14.625 azioni a 135,42 USD e su 6.125 e 1.750 azioni a 146,03 USD tramite trust familiari, poi ha venduto 14.625 azioni e 7.875 azioni a 417,4965 USD.

Dopo queste transazioni, le partecipazioni indirette riportate includono 130 azioni tramite un trust. I titoli derivati di proprietà successiva alle transazioni includono 55.875 opzioni (Trust (2)) e 18.375 opzioni (Trust (3)), con date di vesting ed espirazione specificate.

United Therapeutics (UTHR): El Presidente y el Director de Operaciones reportaron ejercicios de opciones y ventas de acciones relacionadas el 27/10/2025 bajo un plan Rule 10b5-1 con fecha 3 de junio de 2025. La persona reportante ejerció opciones sobre 14.625 acciones a 135,42 USD y sobre 6.125 y 1.750 acciones a 146,03 USD a través de fidecomisos familiares, luego vendió 14.625 acciones y 7.875 acciones a 417,4965 USD.

Después de estas transacciones, las participaciones indirectas mostradas incluyen 130 acciones por un fideicomiso. Los valores derivados de propiedad de modo ventajoso tras las transacciones incluyen 55.875 opciones (Fideicomiso (2)) y 18.375 opciones (Fideicomiso (3)), con fechas de vesting y expiración especificadas.

United Therapeutics (UTHR): 사장 겸 COO는 2025년 10월 27일에 2025년 6월 3일자로 dated된 Rule 10b5-1 계획에 따라 옵션 행사와 관련 주식 매도를 보고했습니다. 보고자는 14,625주를 135.42달러에, 6,125주와 1,750주를 146.03달러에 가족 신탁을 통해 행사한 후, 14,625주와 7,875주를 각각 417.4965달러에 매도했습니다.

이 거래 이후 간접 보유는 하나의 신탁이 보유한 130주를 포함합니다. 거래 이후 실질적으로 소유된 파생증권은 55,875주 옵션(신탁(2))과 18,375주 옵션(신탁(3))으로, 명시된 가용성 및 만료일이 포함됩니다.

United Therapeutics (UTHR): Le président et le directeur des opérations ont signalé des exercices d’options et des ventes d’actions associées le 27/10/2025 dans le cadre d’un plan Rule 10b5-1 daté du 3 juin 2025. La personne faisant le rapport a exercé des options sur 14 625 actions à 135,42 USD et sur 6 125 et 1 750 actions à 146,03 USD via des fiducies familiales, puis a vendu 14 625 actions et 7 875 actions à 417,4965 USD.

Suite à ces transactions, les participations indirectes indiquées comprennent 130 actions par une fiducie. Les titres dérivés détenus à la suite des transactions comprennent 55 875 options (Fiducie (2)) et 18 375 options (Fiducie (3)), avec les dates d’acquisition et d’expiration spécifiées.

United Therapeutics (UTHR): Der Präsident und COO berichteten über Ausübungen von Optionen und damit verbundene Aktienverkäufe am 27.10.2025 im Rahmen eines Rule-10b5-1-Plans vom 03.06.2025. Die meldepflichtige Person hat Optionen über 14.625 Aktien zu 135,42 USD und über 6.125 und 1.750 Aktien zu 146,03 USD über Familienstiftungen ausgeübt, danach wurden 14.625 Aktien und 7.875 Aktien zu 417,4965 USD verkauft.

Nach diesen Transaktionen zeigen indirekte Beteiligungen 130 Aktien durch einen Trust. Die derivativen Wertpapiere, die nach den Transaktionen vorteilhaft besessen werden, umfassen 55.875 Optionen (Trust (2)) und 18.375 Optionen (Trust (3)) mit jeweils festgelegten Vesting- und Ablaufdaten.

United Therapeutics (UTHR): أبلغ الرئيس ونائب رئيس العمليات عن ممارسات خيار ورجوعها وبيع الأسهم المرتبطة في 27/10/2025 بموجب خطة Rule 10b5-1 المؤرخة في 3 يونيو 2025. قامت الشخص المبلِّغ عن упражاء خيارات لــ 14,625 سهماً بسعر 135.42 دولارًا و6,125 و1,750 سهماً بسعر 146.03 دولارًا عبر أمانة عائلية، ثم باع 14,625 سهماً و7,875 سهماً بسعر 417.4965 دولارًا.

بعد هذه المعاملات، تشمل الحيازات غير المباشرة المعروضة 130 سهماً عبر أمانة واحدة. تشمل الأوراق المالية المشتقة المملوكة بموجب المعاملات 55,875 خياراً (Trust (2)) و18,375 خياراً (Trust (3))، مع تواريخ الاستحقاق والاستحقاق المحددة.

United Therapeutics (UTHR): 总裁兼首席运营官在2025-10-27根据2025-06-03日期的 Rule 10b5-1 计划报告了期权行权和相关股票出售情况。报告人以每股135.42美元的价格行使14,625股期权,以每股146.03美元通过家庭信托行使6,125股和1,750股,然后以每股417.4965美元的价格出售14,625股和7,875股。

在这些交易之后,显示的间接持有包括一个信托持有的130股。交易后拥有的派生证券包括55,875份期权(信托(2))和18,375份期权(信托(3)),并有规定的归属和到期日。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BENKOWITZ MICHAEL

(Last) (First) (Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MD 20910

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND COO
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/27/2025 M(1) 14,625 A $135.42 14,625 I by Trust(2)
Common Stock 10/27/2025 S(1) 14,625 D $417.4965 0.00 I by Trust(2)
Common Stock 10/27/2025 M(1) 6,125 A $146.03 6,125 I by Trust(3)
Common Stock 10/27/2025 M(1) 1,750 A $146.03 7,875 I by Trust(3)
Common Stock 10/27/2025 S(1) 7,875 D $417.4965 130 I by Trust(3)
Common Stock 2,648 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options $135.42 10/27/2025 M(1) 14,625 03/15/2023 03/15/2026 Common Stock 14,625 $0.00 55,875 I Trust(2)
Stock Options $146.03 10/27/2025 M(1) 6,125 03/15/2023 03/15/2026 Common Stock 6,125 $0.00 18,375 I by Trust(3)
Stock Options $146.03 10/27/2025 M(1) 1,750 03/15/2018 03/15/2027 Common Stock 1,750 $0.00 0.00 I by Trust(3)
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.
2. Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.
3. Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney 10/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

19.04B
44.43M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING